Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies

Respondek, Gesine ; Grimm, Max Joseph ; Piot, Ines ; Arzberger, Thomas ; Compta, Yaroslau ; Englund, Elisabet LU orcid ; Ferguson, Leslie W. ; Gelpi, Ellen ; Roeber, Sigrun and Giese, Armin , et al. (2020) In Movement Disorders 35(1). p.171-176
Abstract

Background: The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4-repeat (4R)-tauopathy” for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. Objectives: To validate the accuracy of these clinical criteria for “probable 4R-tauopathy” to predict underlying 4R-tauopathy pathology. Methods: Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies).... (More)

Background: The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4-repeat (4R)-tauopathy” for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. Objectives: To validate the accuracy of these clinical criteria for “probable 4R-tauopathy” to predict underlying 4R-tauopathy pathology. Methods: Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies). Results: We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non-4R-tauopathies (N = 161). Sensitivity and specificity of “probable 4R-tauopathy” was 10% and 99% in the first year and 59% and 88% at final record. Conclusions: The new diagnostic category “probable 4R-tauopathy” showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tauopathy. The low sensitivity underpins the need for diagnostic biomarkers.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
corticobasal degeneration, diagnostic criteria, Four-repeat tauopathies, progressive supranuclear palsy
in
Movement Disorders
volume
35
issue
1
pages
6 pages
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:31571273
  • scopus:85073963867
ISSN
0885-3185
DOI
10.1002/mds.27872
language
English
LU publication?
yes
id
95e4d869-6a15-47c3-8689-3d8bd625060b
date added to LUP
2019-11-06 16:26:17
date last changed
2024-04-02 19:56:20
@article{95e4d869-6a15-47c3-8689-3d8bd625060b,
  abstract     = {{<p>Background: The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4-repeat (4R)-tauopathy” for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. Objectives: To validate the accuracy of these clinical criteria for “probable 4R-tauopathy” to predict underlying 4R-tauopathy pathology. Methods: Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies). Results: We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non-4R-tauopathies (N = 161). Sensitivity and specificity of “probable 4R-tauopathy” was 10% and 99% in the first year and 59% and 88% at final record. Conclusions: The new diagnostic category “probable 4R-tauopathy” showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tauopathy. The low sensitivity underpins the need for diagnostic biomarkers.</p>}},
  author       = {{Respondek, Gesine and Grimm, Max Joseph and Piot, Ines and Arzberger, Thomas and Compta, Yaroslau and Englund, Elisabet and Ferguson, Leslie W. and Gelpi, Ellen and Roeber, Sigrun and Giese, Armin and Grossman, Murray and Irwin, David J. and Meissner, Wassilios G. and Nilsson, Christer and Pantelyat, Alexander and Rajput, Alex and van Swieten, John C. and Troakes, Claire and Höglinger, Günter U.}},
  issn         = {{0885-3185}},
  keywords     = {{corticobasal degeneration; diagnostic criteria; Four-repeat tauopathies; progressive supranuclear palsy}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{171--176}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Movement Disorders}},
  title        = {{Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies}},
  url          = {{http://dx.doi.org/10.1002/mds.27872}},
  doi          = {{10.1002/mds.27872}},
  volume       = {{35}},
  year         = {{2020}},
}